1012-91-5

Usage

Uses

Used in Pharmaceutical Research:
1-(2,6-DIMETHYLPHENYL)PIPERAZINE is used as a research compound for its potential psychoactive properties, given its affinity for serotonin and dopamine receptors. This makes it a valuable tool in the study and development of treatments for neurological disorders.
Used in Medicinal Chemistry:
1-(2,6-DIMETHYLPHENYL)PIPERAZINE is used as a starting material or intermediate in the synthesis of other pharmaceutical compounds, contributing to the creation of new drugs with potential therapeutic applications.
Used in Neurological Disorder Treatment:
1-(2,6-DIMETHYLPHENYL)PIPERAZINE is used as a potential therapeutic agent for the treatment of various neurological disorders, leveraging its interaction with key neurotransmitter receptors to modulate their activity and potentially alleviate symptoms.

InChI:InChI=1/C12H18N2/c1-10-4-3-5-11(2)12(10)14-8-6-13-7-9-14/h3-5,13H,6-9H2,1-2H3

Upstream product

• 110-85-0 piperazine 
• 6781-98-2 2,6-dimethyl-1-chlorobenzene 
• 1012-92-6 1-(2,6-dimethylphenyl)piperazine hydrochloride 
• 576-22-7 2-Bromo-m-xylene 

Downstream Products

• 77368-04-8 1-dichloroacetyl-4-(2,6-dimethyl-phenyl)-piperazine 
• 791-93-5 1-(2,6-dimethyl-phenyl)-4-trifluoroacetyl-piperazine 
• 90126-02-6 1-(2,6-Dimethyl-phenyl)-4-(2-pyridin-2-yl-ethyl)-piperazine; compound with (E)-but-2-enedioic acid 
• 131028-00-7 1-{2-[4-(2,6-Dimethyl-phenyl)-piperazin-1-yl]-2-oxo-ethyl}-pyrrolidin-2-one 
• 112253-20-0 2-[4-(2,6-Dimethyl-phenyl)-piperazin-1-yl]-benzaldehyde 
• 118778-78-2 1-<3-(5-methyl-1,3,4-oxadiazol-2-yl)phenoxy>-3-<4-(2,6-dimethylphenyl)-1-piperazinyl>-2-propanol 
• 177488-43-6 N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-4-(2,6-dimethylphenyl)piperazin-1-ylamide fumarate 
• 80305-34-6 N-(3,4,5-trimethoxy-benzyl)-N'-(2,6-dimethylphenyl)-piperazine hydrochloride 

Relevant academic research and scientific papers

Ligand-based rational design, synthesis and evaluation of novel potential chemical chaperones for opsin

Inherited blinding diseases retinitis pigmentosa (RP) and a subset of Leber's congenital amaurosis (LCA) are caused by the misfolding and mistrafficking of rhodopsin molecules, which aggregate and accumulate in the endoplasmic reticulum (ER), leading to photoreceptor cell death. One potential therapeutic strategy to prevent the loss of photoreceptors in these conditions is to identify opsin-binding compounds that act as chemical chaperones for opsin, aiding its proper folding and trafficking to the outer cell membrane. Aiming to identify novel compounds with such effect, a rational ligand-based approach was applied to the structure of the visual pigment chromophore, 11-cis-retinal, and its locked analogue 11-cis-6mr-retinal. Following molecular docking studies on the main chromophore binding site of rhodopsin, 49 novel compounds were synthesized according to optimized one-to seven-step synthetic routes. These agents were evaluated for their ability to compete for the chromophore binding site of opsin, and their capacity to increase the trafficking of the P23H opsin mutant from the ER to the cell membrane. Different new molecules displayed an effect in at least one assay, acting either as chemical chaperones or as stabilizers of the 9-cis-retinal-rhodopsin complex. These compounds could provide the basis to develop novel therapeutics for RP and LCA.

Design, synthesis, and biological evaluation of structurally constrained hybrid analogues containing ropinirole moiety as a novel class of potent and selective dopamine D3 receptor ligands

Two series of hybrid analogues were designed, synthesized, and evaluated as a novel class of selective ligands for the dopamine D3 receptor. Binding affinities of target compounds were determined (using the method of radioligand binding assay). Compared to comparator agent BP897, compounds 2a and 2c were found to demonstrate a considerable binding affinity and selectivity for D3 receptor, and especially compound 2h was similarly potent and more selective D3R ligand than BP897, a positive reference. Thus, they may provide valuable information for the discovery and development of highly potent dopamine D3 receptor ligands with outstanding selectivity.

Pd-Catalyzed Synthesis of Piperazine Scaffolds under Aerobic and Solvent-Free Conditions

A facile Pd-catalyzed methodology providing an efficient synthetic route to biologically relevant arylpiperazines under aerobic conditions is reported. Electron donating and sterically hindered aryl chlorides were aminated to afford yields up to 97%, with examples using piperazine as solvent, illustrating an ecofriendly, cost-effective synthesis of these privileged structures.